IPO Year: 2020
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/7/2025 | $30.00 | Sector Outperform | Scotiabank |
| 2/10/2025 | $40.00 | Outperform | Oppenheimer |
| 8/20/2024 | Overweight | Cantor Fitzgerald | |
| 8/13/2024 | $18.00 → $22.00 | Outperform → Strong Buy | Raymond James |
| 8/12/2024 | $19.00 → $20.00 | Outperform | Leerink Partners |
| 7/25/2024 | $18.00 | Outperform | Raymond James |
| 3/5/2024 | $6.00 → $18.00 | Market Perform → Outperform | Leerink Partners |
| 2/20/2024 | Mkt Perform → Outperform | William Blair | |
| 9/20/2023 | Outperform → Mkt Perform | William Blair | |
| 1/31/2023 | $10.00 | Outperform | Wedbush |
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
144 - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
144 - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
10-Q - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
DEFA14A - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
DEF 14A - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
144 - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
SCHEDULE 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
S-8 - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
Scotiabank initiated coverage of ARS Pharmaceuticals with a rating of Sector Outperform and set a new price target of $30.00
Oppenheimer initiated coverage of ARS Pharmaceuticals with a rating of Outperform and set a new price target of $40.00
Cantor Fitzgerald initiated coverage of ARS Pharmaceuticals with a rating of Overweight
Raymond James upgraded ARS Pharmaceuticals from Outperform to Strong Buy and set a new price target of $22.00 from $18.00 previously
Leerink Partners reiterated coverage of ARS Pharmaceuticals with a rating of Outperform and set a new price target of $20.00 from $19.00 previously
Raymond James initiated coverage of ARS Pharmaceuticals with a rating of Outperform and set a new price target of $18.00
Leerink Partners upgraded ARS Pharmaceuticals from Market Perform to Outperform and set a new price target of $18.00 from $6.00 previously
William Blair upgraded ARS Pharmaceuticals from Mkt Perform to Outperform
William Blair downgraded ARS Pharmaceuticals from Outperform to Mkt Perform
Wedbush initiated coverage of ARS Pharmaceuticals with a rating of Outperform and set a new price target of $10.00